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INTRODUCTION 
                                          
 
             Atherosclerosis is a  inflammatory  disease  affecting the large 
and  medium sized  blood  vessels.Serum  levels of C-reactive protein, a  
major acute phase  protein represents a clinical marker of inflammation.               
           Recent  data has  revealed  that CRP has been  positively been 
associated  with  atherosclerosis. CRP  has been found to be positively 
associated  with acute myocardial infarction  and with sudden deaths in 
patients with stable and unstable angina.(1)Baseline levels of CRP in 
healthy subjects have been  shown to predict development of 
symptomatic peripheral vascular disease. Coronary artery  disease or 
both.(2)   
               An  association between CRP and  number of stenosed  
coronary vessels  has been documented in coronary atherosclerosis.(3)In 
relation to carotid atherosclerosis, two studies have  shown the  relation 
between CRP  levels and  carotid plaques.In one  study there was a 
significant relation  between CRP and early non-stenotic 
atherosclerosis.(4)In anotherstudy  there was correlation  between CRP 
levels and prescence of atherosclerosis in the coronary, extracranial 
cerebrovascular and in the vasculature of the extremities.(5) Patients 
without any of the conventional risk 
factors[smoking,diabetesmellitus,hypertension,dyslipidemia] for 
atherosclerosis are  considered to be at low risk. 
 
  As  demonstrated in one study CRP is of special value only in patients in 
whom at least one of the four major risk factors are present.CRP is a 
proven risk factor in hypercholesteremic patients.(6)Hence this study was 
focused on a  group of dyslipidemic\ patients.      
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
                                             AIM  OF  THE  STUDY  
 
 
       The aim of  the study is to determine whether  CRP  concentrations 
correlated with the  prescence    of  carotid  atherosclerotic plaques in a 
subset of dyslipidemic patients.  available on 
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LITERATURE REVIEW 
Atherosclerosis is an inflammatory disease. Because high plasma 
concentrations of  cholesterol, in particular those of low-density 
lipoprotein (LDL) cholesterol, are one of the principal risk factors for 
atherosclerosis(7) the process of atherogenesis has been considered by 
many to consist largely of the accumulation of lipids within the artery 
wall; . In fact, the lesions of atherosclerosis  represent a series of highly 
specific  cellular and molecular responses that can best be described, in 
aggregate, as an  inflammatory disease. The lesions of atherosclerosis 
occur principally in large and medium-sized elastic and muscular 
arteries and can lead to ischemia of the heart, brain, or extremities, 
resulting in infarction. They may be present throughout a person's 
lifetime. In fact, the earliest type of lesion, the so-called fatty streak, 
which is common in infants and young children, is a pure inflammatory 
lesion, consisting only of monocyte-derived macrophages and T 
lymphocytes.(8) In persons with hypercholesterolemia, the influx of these 
cells is  preceded by the extracellular deposition of amorphous and 
membranous lipids..  
 
 
FACTORS THAT  INDUCE AND PROMOTE ATHEROGENESIS 
OR INFLAMMATION  
Numerous pathophysiologic observations in humans and animals 
led to the formulation of  the response-to-injury hypothesis of 
atherosclerosis, which initially proposed that endothelial denudation was 
the first step in atherosclerosis.(9) The most recent version of this 
hypothesis emphasizes endothelial dysfunction rather than denudation. 
Whichever process is at work, each characteristic lesion of 
atherosclerosis represents a different stage in a chronic inflammatory 
process in the artery; if unabated and excessive, this  process will result 
in an advanced, complicated lesion. Possible causes of endothelial  
dysfunction leading to atherosclerosis include elevated and modified LDL; 
free radicals caused by cigarette smoking, hypertension, and diabetes 
mellitus; genetic alterations;  elevated plasma homocysteine 
concentrations; infectious microorganisms such as  herpesviruses or 
Chlamydia pneumoniae; and combinations of these or other factors. 
 Regardless of the cause of endothelial dysfunction, atherosclerosis 
is a highly characteristic response of particular arteries. The endothelial 
dysfunction that results from the injury leads to compensatory responses 
that alter the normal homeostatic properties of the endothelium. Thus, 
the different forms of injury increase the adhesiveness of the endothelium 
with respect to leukocytes or  platelets, as well as its permeability. The 
injury also induces the endothelium to have  procoagulant instead of 
anticoagulant properties and to form vasoactive molecules,  cytokines, 
and growth factors. If the inflammatory response does not effectively  
neutralize or remove the offending agents, it can continue indefinitely. In 
doing so, the  inflammatory response stimulates migration and 
proliferation of smooth-muscle cells that  become intermixed with the 
area of inflammation to form an intermediate lesion. If these  responses 
continue unabated, they can thicken the artery wall, which compensates 
by  gradual dilation, so that up to a point, the lumen remains 
unaltered,(10) a phenomenon termed "remodeling." As for the 
inflammatory cells, granulocytes are rarely present  during any phase of 
atherogenesis. Instead, the response is mediated by monocyte -derived 
macrophages and specific subtypes of T lymphocytes at every stage of the 
disease. 
 Continued inflammation results in increased numbers of 
macrophages and lymphocytes,  which both emigrate from the blood and 
multiply within the lesion. Activation of these  cells leads to the release of 
hydrolytic enzymes, cytokines, chemokines, and growth  factors, which 
can induce further damage and eventually lead to focal necrosis.(11)   
Thus, cycles of accumulation of mononuclear cells, migration and 
proliferation of  smooth-muscle cells, and formation of fibrous tissue lead 
to further enlargement and  restructuring of the lesion, so that it 
becomes covered by a fibrous cap that overlies a core  of lipid and 
necrotic tissue — a so-called advanced, complicated lesion. At some 
point,  the artery can no longer compensate by dilation; the lesion may 
then intrude into the  lumen and alter the flow of blood. 
HYPERCHOLESTEROLEMIA AND MODIFIED LIPIDS AND 
LIPOPROTEINS 
Lipids, which may be modified by oxidation, glycation (in diabetes), 
aggregation , association with proteoglycans, or incorporation into 
immune complexes,(12) is a  major cause of injury to the endothelium and 
underlying smooth muscle When  LDL particles become trapped in an 
artery, they can undergo progressive oxidation and  be internalized by 
macrophages by means of the scavenger receptors on the surfaces of  
these cells.(13) The internalization leads to the formation of lipid peroxides 
and  facilitates the accumulation of cholesterol esters, resulting in the 
formation of foam cells.  
  The degree to which LDL is modified can vary greatly.(13) Once 
modified and taken  up by macrophages, LDL activates the foam cells. 
Removal and sequestration of  modified LDL are important parts of the 
initial, protective role of the macrophage in the  inflammatory response 
and minimize the effects of modified LDL on endothelial  and smooth-
muscle cells. Antioxidants such as vitamin E can also reduce free-radical  
formation by modified LDL. In addition to its ability to injure these cells, 
modified   
LDL is chemotactic for other monocytes and can up-regulate the 
expression of genes for  macrophage colony-stimulating factor and 
monocyte chemotactic protein derived  from endothelial cells. Thus, it 
may help expand the inflammatory response by  stimulating the 
replication of monocyte-derived macrophages and the entry of new  
monocytes into lesions.  
The inflammatory response itself can have a profound effect on 
lipoprotein movement  within the artery. Specifically, mediators of 
inflammation such as tumor necrosis factor  , interleukin-1, and 
macrophage colony-stimulating factor increase binding of LDL to  
endothelium and smooth muscle and increase the transcription of the 
LDL-receptor  gene.(14) After binding to scavenger receptors in vitro, 
modified LDL initiates a series of  intracellular events(15) that include the 
induction of urokinase and inflammatory  cytokines such as interleukin-
1. Thus, a vicious circle of inflammation,  modification of lipoproteins, 
and further inflammation can be maintained in the artery by  the 
presence of these lipids. 
  Oxidized LDL is present in lesions of atherosclerosis in humans.(16) 
In animals with  hypercholesterolemia, antioxidants can reduce the size 
of lesions, and they  reduce fatty streaks in nonhuman primates. The 
latter observation suggests that the  antioxidants have an 
antiinflammatory effect, perhaps by preventing the up-regulation of 
adhesion molecules for monocytes. Antioxidants increase the resistance 
of human LDL to oxidation ex vivo(17) in proportion to the vitamin E 
content of the plasma. Vitamin E  intake is inversely correlated with the 
incidence of myocardial infarction, and vitamin E  supplementation 
reduced coronary events in a preliminary clinical trial In contrast,  other 
antioxidants, such as beta carotene, have no benefit 
.HOMOCYSTEINE  
High plasma homocysteine concentrations were initially thought to 
be associated with  advanced atherosclerosis on the basis of autopsy 
findings in patients with homozygous  defects in enzymes necessary for 
homocysteine metabolism, such as cystathionine beta -synthase or 
methylenetetrahydrofolate reductase.(18) In patients with such defects,  
severe atherosclerosis develops in childhood, and many have their first 
myocardial  infarction by the age of 20 years Homocysteine is toxic to 
endothelium(19) and is  prothrombotic, and it increases collagen 
production and decreases the availability of  nitric oxide. 
  Plasma homocysteine concentrations are slightly elevated in many 
patients who have no  enzymatic defects in homocysteine metabolism. 
These patients have an increased risk  of symptomatic atherosclerosis of 
the coronary, peripheral, and cerebral arteries  Treatment with folic acid 
can return their plasma homocysteine concentrations to normal.  Trials 
are under way to determine whether folic acid will prevent the 
progression or  possibly even induce the regression of atherosclerotic 
lesions. 
 HYPERTENSION 
Concentrations of angiotensin II, the principal product of the 
renin–angiotensin system,  are often elevated in patients with 
hypertension; angiotensin II is a potent  vasoconstrictor. In addition to 
causing hypertension, it can contribute to atherogenesis by  stimulating 
the growth of smooth muscle.(20) Angiotensin II binds to specific receptors 
on  smooth muscle, resulting in the activation of phospholipase C, which 
can lead to  increases in intracellular calcium concentrations and in 
smooth-muscle contraction,   increased protein synthesis, and smooth-
muscle hypertrophy. It also increases smooth -muscle lipoxygenase 
activity, which can increase inflammation and the oxidation of  LDL. 
Hypertension also has proinflammatory actions, increasing the formation 
of  hydrogen peroxide and free radicals such as superoxide anion and 
hydroxyl radicals in  plasma. These substances reduce the formation of 
nitric oxide by the  endothelium,(21) increase leukocyte adhesion and 
increase peripheral resistance. Thus,  free-radical formation mediates 
some of the effects of both hypertension and  hypercholesterolemia. 
 
 
INFECTION 
Several reports have shown a correlation between the incidence of 
atherosclerosis and the  presence of at least two types of infectious 
microorganisms, herpesviruses and C.  pneumoniae(22) Both organisms 
have been identified in atheromatous lesions in  coronary arteries and in 
other organs obtained at autopsy. Increased titers of  antibodies to these 
organisms have been used as a predictor of further adverse events in  
patients who have had a myocardial infarction. Nonetheless, there is no 
direct evidence that these organisms can cause the lesions of 
atherosclerosis.  
Although these organisms are ubiquitous in many tissues and 
organs, the fact that lesions cannot be induced experimentally in animals 
by injection of the organisms leaves their role as etiologic agents in 
question. It is nevertheless possible that infection, combined with other 
factors, may be responsible for the genesis of the lesions of 
atherosclerosis in some patients. 
 THE NATURE OF THE INFLAMMATORY RESPONSE 
Interactions among Endothelial Cells, Monocytes, and T Cells  
Specific arterial sites, such as branches, bifurcations, and 
curvatures, cause characteristic alterations in the flow of blood, including 
decreased shear stress and increased turbulence.(23) At these sites, 
specific molecules form on the endothelium that are responsible for the 
adherence, migration, and accumulation of monocytes and T cells.  
Such adhesion molecules, which act as receptors for 
glycoconjugates and integrins present on monocytes and T cells, include 
several selectins, intercellular adhesion molecules, and vascular-cell 
adhesion molecules.(24) Molecules associated with the migration of 
leukocytes across the endothelium, such as platelet–endothelial-cell 
adhesion molecules,(25) act in conjunction with chemoattractant 
molecules generated by the endothelium, smooth muscle, and monocytes 
— such as monocyte chemotactic protein 1 osteopontin to bind to 
monocytes and other WBC.,  
The nature of the flow — that is, whether shear stress or 
turbulence is high or low — appears to be important in determining 
whether lesions occur at these vascular sites. Changes in flow alter the 
expression of genes that have elements in their promoter regions that 
respond to shear stress. For example, the genes for intercellular adhesion 
molecule 1, platelet-derived growth factor B chain, and tissue factor in 
endothelial cells have these elements, and their expression is increased 
by reduced shear stress.(26)  
Thus, alterations in blood flow appear to be critical in determining 
which arterial sites are prone to have lesions Rolling and adherence of 
monocytes and T cells occur at these sites as a result of the up-
regulation of adhesion molecules on both the endothelium and the 
leukocytes.  
Chemokines may be responsible for the chemotaxis and 
accumulation of macrophages in fatty streaks.(27) Activation of monocytes 
and T cells leads to up-regulation of receptors on their surfaces, such as 
the mucin-like molecules that bind selectins, integrins that bind 
adhesion molecules of the immunoglobulin superfamily, and receptors 
that bind  chemoattractant molecules(28]  . These ligand–receptor 
interactions further activate mononuclear cells, induce cell proliferation, 
and help define and localize the inflammatory response at the sites of 
lesions. In genetically modified mice that are deficient in apolipoprotein E 
(and have hypercholesterolemia), intercellular adhesion molecule 1 is 
constitutively increased at lesion-prone sites.(29) In fact, it is present on 
the surface of the endothelium at these sites  in  normal mice and is 
increased in mice with apolipoprotein E deficiency. In contrast, vascular-
cell adhesion molecule 1 is absent in normal mice but is present at the 
same sites as intercellular adhesion molecule 1 in mice with 
apolipoprotein E deficiency.  
Thus, adherence of monocytes and T cells may occur after an 
increase in one or more of the adhesion molecules, which may act in 
concert with chemotactic molecules such as monocyte chemotactic 
protein 1, interleukin-8, or modified LDL.  In mice that are  completely  
deficient in intercellular adhesion molecule 1, P-selectin, CD18, or   
combinations of these   molecules, lipid feeding leads to smaller lesions of  
atherosclerosis.(30) Comparison of the   relative roles of these molecules in 
inflammation   in the arteries and the microvasculature   may provide 
clues to the relative feasibility of  modifying the inflammatory process at   
these sites, and thus of modifying  therosclerosis.  
 
METALLOPROTEINASE LIKE PROTEINS 
A  recently discovered class of molecules, the disintegrins, 
sometimes called metalloproteinase-like, disintegrin-like, cysteine-rich 
proteins (MDCs), has been identified in endothelium, smooth muscle, and 
macrophages. These transmembrane proteins, which appear to be 
involved in cell–cell interactions, contain a metalloproteinase sequence in 
their extracellular segment that permits them to activate molecules such 
as tumor necrosis factor . They are not found in normal arteries, but 
one of them, MDC15, is present in lesions of atherosclerosis. Adhesion 
molecules such as L-selectin can be cleaved from the surface of 
leukocytes by a metalloproteinase (L-selectin sheddase), which suggests 
that in situations of chronic inflammation it may be possible to measure 
the "shed" molecules, such as the different adhesion molecules, in 
plasma, as markers of a sustained inflammatory response.(31) 
Disintegrins may participate in these shedding processes. If shedding 
occurs, it may be detectable in different types of inflammatory responses. 
Increased plasma concentrations of shed molecules might then be used 
to identify patients at risk for atherosclerosis or other inflammatory 
diseases. 
 MONOCYTES AND IMMUNITY  
The ubiquitous monocyte, the precursor of macrophages in all 
tissues, is present in every phase of atherogenesis. Monocyte-derived 
macrophages are scavenging and antigen-presenting cells, and they 
secrete cytokines, chemokines, growth-regulating molecules, and 
metalloproteinases and other hydrolytic enzymes. The continuing entry, 
survival, and replication of mononuclear cells in lesions depend in part 
on factors such as macrophage colony-stimulating factor and 
granulocyte–macrophage colony-stimulating factor for monocytes and 
interleukin-2 for lymphocytes. Continued exposure to macrophage 
colony-stimulating factor permits macrophages to survive in vitro and 
possibly to multiply within the lesions. In contrast, inflammatory 
cytokines such as interferon-  activate macrophages and under certain 
circumstances induce them to undergo programmed cell death 
(apoptosis). If this occurs in vivo, macrophages may become involved in 
the necrotic cores characteristic of advanced, complicated lesions.  
  Initially, the only cells thought to proliferate during expansion of 
atherosclerotic lesions were smooth-muscle cells. However, replication of 
monocyte-derived macrophages and T cells is probably of equal 
importance.(32) The ability of macrophages to produce cytokines (such as 
tumor necrosis factor , interleukin-1, and transforming growth factor ß), 
proteolytic enzymes (particularly metalloproteinases), and growth factors 
(such as platelet-derived growth factor and insulin-like growth factor I) 
may be critical in the role of these cells in the damage and repair that 
ensue as the lesions progress. Macrophagesexpress class II 
histocompatibility antigens such as HLA-DR that allow them to present 
antigens to T lymphocytes. Thus, it is not surprising that cell-mediated 
immune responses may be involved in atherogenesis, since both CD4 and 
CD8 T cells are present in the lesions at all stages of the process. T cells 
are activated when they bind antigen processed and presented by 
macrophages. T-cell activation results in the secretion of cytokines, 
including interferon-  and tumor necrosis factor and ß, that amplify the 
inflammatory response. Smooth-muscle cells from the lesions also have 
class II HLA molecules on their surfaces, presumably induced by 
interferon- , and can also present antigens to T cells. One possible 
antigen may be oxidized LDL, which can be produced by macrophages. 
Heat-shock protein 60 may also contribute to autoimmunity. This and 
other heat-shock proteins perform several functions, including the 
assembly, intracellular transport, and breakdown of proteins and the 
prevention of protein denaturation. These proteins may be elevated on 
endothelial cells and participate in immune responses. 
 An immunoregulatory molecule, CD40 ligand, can be expressed by 
macrophages, T cells, endothelium, and smooth muscle in 
atherosclerotic lesions in vivo, and its receptor, CD40, is expressed on 
the same cells. Both are up-regulated in lesions of atherosclerosis, 
providing further evidence of immune activation in the lesions. 
Furthermore, CD40 ligand induces the release of interleukin-1ß by 
vascular cells, potentially enhancing the inflammatory response. 
Inhibition of CD40 with blocking antibodies reduces lesion formation in 
apolipoprotein E–deficient mice.  
PLATELETS  
Platelet adhesion and mural thrombosis are ubiquitous in the 
initiation and generation of the lesions of atherosclerosis in animals and 
humans. Platelets can adhere to dysfunctional endothelium, exposed 
collagen, and macrophages. When activated, platelets release their 
granules, which contain cytokines and growth factors that, together with 
thrombin, may contribute to the migration and proliferation of smooth-
muscle cells and monocytes.(33) Activation of platelets leads to the 
formation of free arachidonic acid, which can be transformed into 
prostaglandins such as thromboxane A2, one of the most potent 
vasoconstricting and platelet-aggregating substances known, or into 
leukotrienes, which can amplify the inflammatory response. 
  Plaque rupture and thrombosis are notable complications of 
advanced lesions that lead to unstable coronary syndromes or myocardial 
infarction.(35) Platelets are  important in maintaining vascular integrity in 
the absence of injury and protecting against spontaneous hemorrhage. 
Activated platelets can accumulate on the walls of arteries and recruit 
additional platelets into an expanding thrombus. An important 
component of the platelets is the glycoprotein IIb/IIIa receptor, which 
belongs to the integrin superfamily of adhesion-molecule receptors and 
appears on the surface of platelets during platelet activation and 
thrombus formation. These receptors serve an important hemostatic 
function, and antagonists to them prevent thrombus formation in 
patients who have had a myocardial infarction.  
 ATHEROSCLEROSIS IN RELATION TO OTHER CHRONIC 
INFLAMMATORY DISEASES 
The cellular interactions in atherogenesis are fundamentally no 
different from those in chronic inflammatory–fibroproliferative diseases 
such as cirrhosis, rheumatoid arthritis, glomerulosclerosis, pulmonary 
fibrosis, and chronic pancreatitis.. Thus, the cellular responses in the 
arteries (atherosclerosis), liver (cirrhosis), joints (rheumatoid arthritis), 
kidneys (glomerulosclerosis), lungs (pulmonary fibrosis), and pancreas 
(pancreatitis) are similar yet are characteristic of each tissue or organ.  
 
 INFLAMMATORY RESPONSE  
  Granulocytes are rare in atherosclerosis,they are present only in 
rheumatoid arthritis and pulmonary fibrosis. In the case of arthritis, 
although the early response begins with granulocytes, they are found 
primarily within the joint cavity. Macrophages and lymphocytes 
predominate in the synovium, leading to erosion of cartilage and bone, 
which is replaced by fibrous tissue (pannus). In pulmonary fibrosis, 
granulocytes initially appear in the alveolar spaces; however, the lung 
parenchyma, where fibrosis ultimately occurs, is infiltrated by 
macrophages and lymphocytes. Thus, there are parallels between 
atherosclerosis and these other inflammatory diseases.If the injurious 
agent or agents are not removed or nullified by the inflammatory 
response and the inflammation progresses, the response changes from a 
protective to an injurious response. Such constant or repetitive injury 
can stimulate each tissue to repair or wall off the damage by means of a 
fibroproliferative response, which, when excessive, diminishes the 
functional capacity of the tissue or organ and becomes part of the disease 
process. 
 INSTABILITY AND RUPTURE OF PLAQUE  
Chronic inflammatory responses are often associated with specific 
types of injurious or granuloma-inducing agents. In most patients 
myocardial infarctions occur as a result of erosion or uneven thinning 
and rupture of the fibrous cap, often at the shoulders of the lesion where 
macrophages enter, accumulate, and are activated and where apoptosis 
may occur.(36) Degradation of the fibrous cap may result from elaboration 
of metalloproteinases such as collagenases, elastases, and 
stromelysins.(37) Activated T cells may stimulate metalloproteinase 
production by macrophages in the lesions, which promotes plaque 
instability and further implicates an immune response. These changes 
may also be accompanied by the production of tissue-factor procoagulant 
and other hemostatic factors, further increasing the possibility of 
thrombosis. Stable advanced lesions usually have uniformly dense 
fibrous caps. The potentially dangerous lesions are often nonocclusive 
and thus difficult to diagnose by angiography, yet at autopsy active 
inflammation is evident in the accumulation of macrophages at sites of 
plaque rupture.(34) Macrophage accumulation may be associated with 
increased plasma concentrations of both fibrinogen and C-reactive 
protein, two markers ofinflammation thought to be early signs of 
atherosclerosis Plaque rupture and thrombosis may be responsible for as 
many as 50 percent of cases of acute coronary syndromes and 
myocardial infarction.  
 ROLE OF  SMOOTH MUSCLE 
  Smooth-muscle cells  have different embryonic origins, depending 
on the segment of the arterial system involved. In some vertebrates, 
smooth-muscle cells in the upper portion of the thoracic aorta are 
derived from a neuroectodermal source, whereas those in the abdominal 
aortaare derived from a mesenchymal source. Although likely, this has 
not been confirmed in humans. The smooth-muscle cells of coronary 
arteries appear to originate from a third precursor population in the 
intracardiac mesenchyme. The existence of these different lineages 
suggests that smooth muscle in different parts of the arterial tree may 
respond differently to the stimuli that generate atherosclerotic lesions at 
each of these sites.  
THE ROLE OF THE MATRIX 
 Smooth-muscle cells in the media of arteries, as well as in lesions, 
are surrounded by different types of connective tissue. In the media of 
arteries, the matrix consists largely of type I and III fibrillar collagen, 
whereas in the lesions of atherosclerosis it consists largely of 
proteoglycan, intermixed with loosely scattered collagen fibrils.  
When cultured human arterial smooth-muscle cells are plated on 
collagen in fibrillar form, the collagen inhibits cell proliferation by up-
regulating specific inhibitors of the cell cycle. In vivo degradation of the 
collagen by collagenase, or migration away from this inhibitory 
environment, may allow the smooth-muscle cells to respond to mitogenic 
stimuli and replicate, as they do when they are cultured on nonfibrillar, 
monomeric collagen. Other matrix molecules, such as fibronectin and 
heparan sulfate, may be involved, because they can also inhibit the cell 
cycle, and cell–matrix interactions can lead to the expression of 
chemokines by macrophages. If these interactions were to occur in 
arteries, they could profoundly influence the inflammatory and 
fibroproliferative response. Thus, the matrix that surrounds the cells is 
not neutral and may determine whether they remain quiescent or 
multiply in response to growth factors.  
 C-REACTIVE PROTEIN  AND ROLE IN ATHEROSCLEROSIS 
C-reactive Protein (CRP) is an acute-phase protein produced by the 
liver in response to inflammation or infection. Because inflammation is 
considered an etiologic factor in cardiovascular events such as 
myocardial infarction (MI) and stroke, recent studies have looked at 
inflammation markers as potential predictors of risk for these events.
 The inflammatory marker CRP is one of the most powerful 
independent predictors of myocardial infarction, stroke, and vascular 
death in a variety of settings, with prognostic value extending across 
various ethnic groups and in men and women in different age groups. 
More recently, elegant work by Ridker and colleagues(38) demonstrated 
that CRP may be a better predictor of future cardiovascular events than 
low-density lipoprotein (LDL) cholesterol and that baseline CRP 
evaluation adds prognostic value to the conventional Framingham risk 
assessment.  
The link between CRP and atherosclerosis was initially suggested 
to be that of a "surrogate biomarker" vs. a mediator of atherosclerosis. 
This view has been recently revisited, with observations suggesting that 
CRP has a direct effect to promote atherosclerotic processes and 
endothelial cell inflammation. .  
  EFFECTS OF  CRP ON MACROPHAGE LDL UPTAKE 
.  Uptake of LDL by macrophages is an important process 
contributing to plaque progression. Recent evidence suggests that CRP 
directly promotes native LDL uptake into macrophages, a process that is 
ET-1 dependent and inhibited during coincubation with the ETA/B 
receptor blocker bosentan 
. EFFECTS OF  CRP ON  FIBRINOLYTIC PARAMETERS 
.  Endothelial cells are the major source of plasminogen activator 
inhibitor-1 (PAI-1), and PAI-1 serves to inhibit endogenous fibrinolysis, 
promoting atherothrombosis and progression of acute coronary 
syndromes. Recent evidence suggests that incubation of human coronary 
artery endothelial cells with CRP results in a time- and dose-dependent 
increase in secreted PAI-1 antigen, PAI-1 activity, intracellular PAI-1 
protein, and PAI-1 mRNA.  
 
EFFECTS OF  CRP ON  VASCULAR  SMOOTH  MUSCLE  CELLS AND 
ANGIOTENSIN RECEPTOR REGULATION  
Angiotensin  II is one of the most important proinflammatory 
molecules, capable of promoting diverse proatherosclerotic processes at 
the level of the endothelium and VSM. The angiotensin type 1 receptor 
(AT1-R) is a key atherosclerotic switch facilitating ANG II-induced reactive 
oxygen species (ROS) production, VSM cell migration, proliferation, and 
vascular remodeling. Given the central importance of AT1-R in the 
development and clinical course of atherosclerosis, we recently evaluated 
the effects of CRP on AT1-R and associated pathophysiological processes 
(40). CRP potently upregulates AT1-R mRNA and protein and increases the 
number of AT1-R binding sites in VSM cells. This effect is not related to a 
change in AT1-R mRNA stability, because the half-life of AT1-R transcript 
was similar after incubation with actinomycin-D. Additionally, in VSM 
cells in vitro, CRP markedly stimulated cell migration and proliferation, 
with an effect approaching 75% of that noted with the pro-typical 
stimulant PDGF. The effects of CRP on VSM cells appear to be closely 
related to the expression of AT1-R, because they were inhibited by 
losartan, an angiotensin receptor blocker. CRP also augmented ANG II-
induced VSM cell migration and proliferation, further supporting a 
functional relationship between CRP and ANG II in mediating VSM cell 
pathology. In VSM cells, CRP increased basal ROS production and 
potentiated the effects of ANG II on ROS formation. These effects were 
also inhibited by losartan, indicating that increased CRP-mediated ROS 
formation in VSM cells was related, in part, to increased AT1-R 
expression. Last, in an in vivo model of carotid balloon angioplasty, CRP 
exposure facilitated AT1-R expression, with resultant increases in 
neointimal formation, VSM migration, and proliferation and promoted 
collagen and elastin production, key matrix proteins in the vessel wall. 
These effects were attenuated by angiotensin receptor blockade with 
losartan. Therefore, CRP exerts direct proatherosclerotic effects at the 
level of the VSM (in addition to the endothelium), in part via increased 
AT1-R expression and signaling. No effect of CRP was found on AT2-R, 
which may be vasculoprotective in certain settings. Likewise, we did not 
observe an effect of CRP on ANG II release.  
EFFECT OF CRP ON  BONE MARROW DERIEVED ENDOTHELIAL 
PROGENITOR CELL 
  Postnatal neovascularization is a process that is vital to the 
compensatory physiological response in chronic ischemia. Myocardial 
ischemia provides a potent stimulus to angiogenesis and the subsequent 
development of collateral vasculature that maintains and/or revitalizes 
cardiac tissue. The mobilization and differentiation of bone-marrow 
derived endothelial progenitor cells (EPCs) has recently been shown to be 
important in this process of neovascularization (41). Recently, the number 
and migratory activity of circulating EPCs has also been shown to 
inversely correlate with risk factors for coronary artery disease. In this 
vein, recent work suggests that EPCs incubated with human 
recombinant CRP, at concentrations known to predict adverse vascular 
outcomes, exhibited decreased survival and increased apoptosis (42). This 
reduction in EPC cell number was dose dependent, and at a CRP 
concentration of 20 µg/ml, there was an 80% reduction in cell number 
at 7 days. Additionally, EPCs incubated with human recombinant CRP 
exhibited decreased expression of endothelial cell-specific markers Tie-2 
and endothelial cell-specific lectin, indicating an effect of CRP to inhibit 
EPC differentiation. CRP also caused a significant decrease in EPC eNOS 
mRNA expression after 24 h of incubation. These observations extend the 
proatherogenic effects of CRP, beyond the endothelium and VSM to the 
bone marrow and the systemic response in chronic ischemia..  
            A growing body of evidence implicates CRP as a powerful risk 
marker for diverse cardiovascular and metabolic diseases. Initially, this 
association was suggested to be a surrogate one, wherein CRP functioned 
to highlight increased levels of vascular  inflammation and, in this 
fashion, identify patients at heightened risk of atherothrombosis. Thus 
CRP may not just be a marker of atherosclerosis and coronary events, 
but also a mediator of this disease because it contributes to the substrate 
underlying lesion formation, plaque rupture, and coronary thrombosis.  
 
TREATMENT OF RISK FACTORS: 
 It is useful to group the cardiovascular risk factors that have 
emerged  into two categories: (1) those modifiable by lifestyle and/or 
pharmacotherapy, and (2) those that are essentially unmodifiable . The 
weight of evidence supporting various risk factor differs. For example, 
hypercholesterolemia and hypertension indubitably  predict coronary 
risk, but other so-called nontraditional risk factors, such as levels of  
homocysteine, lipoprotein (a) [Lp(a)], or infection, remain controversial. It 
is worth distinguishing further between factors that actually participate 
in the pathogenesis of atherosclerosis and those that may merely serve 
as markers of risk without themselves playing a primary role in 
pathogenesis.. 
 
LIPID DISORDERS  
Abnormalities in plasma lipoproteins and derangements in lipid 
metabolism rank as the most firmly established and best understood 
risk factors for atherosclerosis.Current national guidelines recommend 
cholesterol screening in all adults. The screen should include a fasting 
lipid profile [total cholesterol, triglycerides, low-density lipoprotein (LDL) 
cholesterol and high-density lipoprotein (HDL) cholesterol]. Dietary 
measures, including specific consultation by practitioners with training 
in nutrition, should be offered to all patients with hyperlipidemia  
.Additional risk factors for coronary heart disease or when the HDL level 
is below 40 mg/dL. Many patients with established atherosclerosis fall 
into this category. Such individuals should receive particular 
encouragement to adopt life-style measures such as diet and exercise 
aimed at increasing their HDL levels.The addition of drug therapy to 
dietary and other nonpharmacologic measures to reduce the risk of 
atherosclerotic events in asymptomatic patients without manifest 
vascular disease remains unsettled. In asymptomatic patients with 
heterozygous familial hypercholesterolemia, LDLlowering by 
pharmacologic measures reduces atherosclerosis in both men and 
women. The West of Scotland Study established that lipid lowering with 
the HMG-CoA inhibitor pravastatin can effectively reduce cardiac events 
and total mortality in a cohort of patients with hypercholesterolemia but 
without prior myocardial infarction . The recent AFCAPS/TexCAPS Study 
showed that treatment with lovastatin similarly reduced coronary events 
in patients without previous myocardial infarction but with "average" 
total and LDL cholesterol levels and somewhat decreased HDL 
levels.Although the role of drug therapy in primary prevention of the 
manifestations of atherosclerosis remains incompletely defined, 
abundant evidence establishes the benefit of drug therapy in  patients 
with hypercholesterolemia and established coronary artery disease . A 
number of well-designed and -executed large-scale clinical trials have 
now shown that treatment with statins reduces recurrent myocardial 
infarction, reduces strokes, and lessens the need for  revascularization 
or hospitalization for unstable angina pectoris. These studies have 
enrolled patients in numerous countries on at least three continents and 
encompass individuals with clearly elevated levels of cholesterol and 
those with "average" total and LDL cholesterol levels.  Lipid-lowering 
therapies do not appear to exert their beneficial effect on cardiovascular 
events by causing a marked "regression" of obstructive coronary lesions. 
Angiographically monitored studies of lipid lowering have shown at best 
a modest reduction in coronary artery stenoses over  the duration of 
study. Yet these same studies consistently show substantial decreases in 
coronary events. These results suggest that the mechanism of benefit of 
lipid lowering does not require a substantial reduction in the fixed 
stenoses. Rather, the benefit may derive from "stabilization" of 
atherosclerotic lesions without decreased stenosis. Such stabilization of 
atherosclerotic lesions and the attendant decrease in coronary events 
may result from the egress  of lipids or by favorably influencing aspects 
of the biology of atherogenesis discussed in . In addition, as sizeable 
lesions may protrude abluminally rather than into the lumen, shrinkage 
of such plaques might not be apparent on angiograms.The benefit of LDL 
lowering by HMG-CoA reductase inhibitor (statin) therapy on 
cardiovascular events seems to require 6 to 24 months of treatment. 
Improvement of vasomotor responses to endothelial-dependent 
vasodilators occurs much more rapidly, requiring 6 months or less. 
Thus, HMG-CoA reductase inhibitors may act by two or more 
mechanisms on the arteries of hypercholesterolemic individuals. The 
relatively rapid improvement in endothelial-dependent vasomotion may 
reflect enhanced production or reduced destruction of the endogenous 
vasodilator nitric oxide at the level of the arterial endothelium. Reduction 
in the thrombotic complications of atherosclerosis, such as myocardial 
infarction or unstable angina, probably requires more prolonged 
treatment to effect removal of lipid from deeper within the 
atheroma,yielding improvements in the biology underlying plaque 
destabilization.Our current understanding of the mechanism by which 
elevated LDL levels promote atherogenesis relates to oxidative 
modification of these particles within the artery wall, promoting 
formation of macrophage-derived foam cells and providing a stimulus for 
inflammation . These concepts have given rise to considerable interest in 
the possibility that antioxidants, either dietary or pharmacologic, might 
reduce atherogenesis. Considerable experimental evidence supports this 
notion. In addition, many observational studies show a correlation of 
antioxidant consumption and reduced cardiovascular risk. Rigorous, 
controlled clinical trial evidence, however, has not yet proven the 
effectiveness of antioxidant therapy, whether dietary or with 
supplements of vitamins or drugs, for prevention or treatment of 
atherosclerosis. Indeed, controlled trials with -carotene have 
demonstrated no reduction in cardiovascular events. For these reasons, 
as its efficacy remains speculative, it is premature to consider 
antioxidant administration as a replacement for established therapies. 
Furthermore, general use of such treatments, particularly in lower risk 
individuals, should await the results of rigorous prospective studies 
designed to define the doses, appropriate patient groups, and evaluate 
the possibility of adverse or unwanted effects of antioxidants. 
HYPERTENSION 
  The preponderance of epidemiologic data supports a relationship 
between hypertension and atherosclerotic risk. Clinical trial evidence 
available since the 1970s established that pharmacologic treatment of 
hypertension can reduce the risk of stroke and heart failure. However, 
clinical trial evidence demonstrating reduced risk of coronary events due 
to antihypertensive therapy has lagged. At present, the combined weight 
of the evidence supports a reduction in coronary risk by antihypertensive 
therapy. Some of the difficulty in demonstrating this benefit may derive 
from the potentially adverse effects of certain classes of antihypertensive 
drugs on the lipid profile, notably, thiazide diuretics and beta-blocking 
agents. Indeed, studies of patients with previous myocardial infarction or 
reduced left ventricular function have shown that treatment with 
angiotensin-converting enzyme (ACE) inhibitors can reduce the risk of 
coronary events, an unanticipated outcome. Therefore "lipid-neutral" 
antihypertensive agents such as ACE inhibitors or 1-adrenergic 
blocking agents merit consideration in patients with other risk factors  
for coronary artery disease or with established atherosclerosis. 
DIABETES MELLITUS AND INSULIN RESISTANCE 
Most patients with diabetes mellitus die of atherosclerosis and its 
complications. Secular trends towards aging of the population and 
increased girth will make type 2 (noninsulin-dependent) diabetes 
mellitus an increasing public health problem in the coming years. The 
criteria for diagnosis of diabetes have recently undergone revision. 
Currently, a fasting plasma glucose level of  (125 mg/dL) establishes the 
diagnosis of diabetes. In the intermediate range, plasma glucose levels 
between (110 and 125 mg/dL) indicate impaired fasting glucose. Thus, 
fasting glucose> (110 mg/dL) indicates abnormal glucose tolerance. 
These definitions based on fasting plasma glucose alone obviate the need 
for performing glucose tolerance tests. A  major feature of elevated 
cardiovascular risk in patients with type 2 diabetes probably relates To 
the abnormal lipoprotein profile associated with insulin resistance 
known as diabetic dyslipidemia. While diabetic patients may often have 
LDL cholesterol levels near average, the  LDL particles tend to be smaller 
and denser and thus more atherogenic . Other features of diabetic 
dyslipidemia include low HDL and elevated triglycerides. Establishing 
that strict glycemic control reduces the risk of macrovascular 
complications of diabetes has proven much more elusive than the 
established beneficial effects on microvascular complications such as 
retinopathy or renal disease. In the absence of clear-cut evidence that 
tight glycemic control reduces coronary risk in diabetic patients, 
attention to other aspects of risk in this patient population assumes 
even greater importance. In this regard, recent clinical trials have 
demonstrated unequivocal benefit of HMG-CoA reductase inhibitor 
therapy in diabetic patients, including those with "average" LDL 
cholesterol levels. Having diabetes places patients in the same risk 
category as those with established atherosclerotic disease. These 
guidelines establish a target LDL cholesterol level of (100 mg/dL) for the 
patient with diabetes. 
MALE GENDER/POSTMENOPAUSAL STATE 
Observational studies have verified excess coronary risk in males 
compared with premenopausal females. After menopause, however, 
coronary risk accelerates in women. At least part of the apparent 
protection against coronary heart disease in premenopausal women 
derives from their relatively higher HDL levels compared with those of 
men. After menopause, HDL values fall in concert with increased 
coronary risk. Estrogen therapy lowers LDL cholesterol and raises HDL 
cholesterol, changes that should decrease coronary risk. A multitude of 
observational studies has suggested that estrogen-replacement therapy 
(ERT) reduces coronary risk. Substantial experimental data support the 
biologic plausibility of a beneficial effect of estrogen in reducing 
atherosclerotic events, but a number of potential confounding factors 
render clinical trials necessary to establish the cardiovascular benefits of 
ERT. In men, high-dose  estrogen treatment caused excess mortality, 
probably due to increased thromboembolic  complications. 
The recently reported Heart and Estrogen/Progestin Replacement 
Study (HERS) has highlighted  the need for clinical trial evidence to 
substantiate the observational and experimental data regarding 
estrogen's beneficial effects on the vasculature and lipid profile. In this 
trial, postmenopausal female survivors of acute myocardial infarction 
were randomized to an estrogen/progestin combination or to placebo.          
This study showed no overall reduction in recurrent coronary events in 
the active treatment arm. Indeed, early in the 5-year course of this trial, 
there was a trend toward an actual increase in vascular events in the 
treated women. As in the previous Coronary Drug Project trial, the 
excess events may have resulted from an increase in thromboembolism. 
HERS does not definitively exclude a potential benefit of other 
combinations of estrogens with progestins or a benefit of estrogens alone 
in patients lacking a uterus. A more prolonged follow-up might have 
disclosed an accrual of benefit in the treatment group, as the excess 
events appeared in the first years of the trial in the treated group. 
Moreover, drugs of the selective estrogen receptor modulator class might 
dissociate the increased risk of breast and/or uterine cancer from 
cardiovascular benefit. This possibility will likewise require randomized 
clinical trial evidence evaluating coronary events to validate widespread 
application.   In the recent clinical   trials with HMG-CoA reductase 
inhibitors, women, when included, have derived benefits at least  
commensurate with those seen in men. Data from HERS itself showed 
that application of lipid-  lowering therapy to female survivors of 
myocardial infarction lagged far behind guidelines.  Choices regarding 
ERT in postmenopausal women remain complex. Physicians should work 
together with women to provide information and help weigh the risks 
and benefits of ERT, taking  personal preferences into account. 
DYSREGULATED COAGULATION OR FIBRINOLYSIS 
Thrombosis ultimately causes the gravest complications of 
atherosclerosis. The propensity to form thrombi and/or to lyse clots once 
they form could clearly influence the manifestations of atherosclerosis. 
Thrombosis provoked by atheroma rupture and subsequent healing 
maypromote plaque growth,. Certain individual characteristics can  
influence thrombosis or fibrinolysis and have received attention as 
potential coronary risk factors.  For example, fibrinogen levels correlate 
with coronary risk and provide information regarding coronary risk 
independent of the lipoprotein profile. Elevated fibrinogen levels might 
promote a thrombotic diathesis. Alternatively, fibrinogen, an acute-phase 
reactant, may serve as a marker of inflammation rather than directly 
participating in the pathogenesis of coronary events.The stability of an 
arterial thrombus depends on the balance between fibrinolytic factors, 
such as plasmin, and inhibitors of the fibrinolytic system, such as 
plasminogen activator inhibitor (PAI) 1. Certain genotypes of the PAI-1 
gene appear to correlate with increased coronary risk. Yet,  
overall, the levels of tissue plasminogen activator and PAI-1 in plasma 
have not proven to add information beyond the lipid profile to 
assessment of cardiovascular risk. Likewise, the role of Lp(a) as a 
modulator of fibrinolysis remains controversial. Apo Lp(a) has high 
homology to plasminogen but lacks the enzymatic activity of this 
fibrinolytic molecule. Thus, Lp(a) might antagonize fibrinolysis, serving 
as a type of "dominant negative" competitor of  plasminogen. However, in 
vivo evidence for this mechanism, and, indeed, the independent   
contribution of Lp(a), is clouded by difficulties in standardizing the 
assays and the highlypolymorphic nature of this protein in humans. 
HOMOCYSTEINE 
A large body of literature suggests a relationship between 
hyperhomocysteinemia and coronary  events. Several mutations in the 
enzymes involved in homocysteine accumulation correlate with  
thrombosis and, in some studies, coronary risk. Although thrombosis 
and atherosclerosis seem intimately linked, direct evidence of an 
atherogenic effect of hyperhomocysteinemia in humans remains weak. 
The role of   hyperhomocysteinemia in atherosclerotic complications, 
however, has  important practical implications. The plasma level of 
homocysteine can vary with diet. Nutritional supplementation with folic 
acid can lower homocysteine levels in many individuals. A substantial   
portion of the elderly population has only a marginal sufficiency of folate  
intake.  Recommending a diet rich in  folate or consumption of 
multivitamin supplements containing folic acid should be considered in  
individuals with atherosclerosis out of proportion to traditional or 
established risk factors and with  elevated levels of homocysteine. The 
possibility that folate treatment might mask pernicious anemia should 
be considered when advising such supplementation. No clinical trial 
evidence  currently establishes a reduction in coronary events in patients 
with hyperhomocysteinemia  treated with folate. 
INFECTION/INFLAMMATION 
Recent years have witnessed a resurgence of interest in the 
possibility that infections may cause or contribute to atherosclerosis. A 
spate of recent publications has furnished evidence in support for a role 
of Chlamydia pneumoniae, cytomegalovirus, or other infectious agents in  
atherosclerosis and restenosis following coronary intervention. Some 
microorganisms exist in human atherosclerotic plaques. However, 
seroepidemiologic evidence for an association  between infection with 
various agents and atherosclerosis remains inconclusive. Several 
ongoing  large trials of antibiotic treatment in survivors of myocardial 
infarction may provide support for an  etiologic or contributory role of 
microbial infection in recurrent coronary events.   
 
LIFE-STYLE MODIFICATION 
 It is important to counsel patients regarding the   health risks of 
tobacco use and provide guidance regarding smoking cessation. 
Likewise,  physicians should advise all patients about prudent dietary 
and exercise habits for maintaining  ideal body weight. . Obesity, 
particularly the male pattern of centripetal or  visceral fat accumulation, 
can promote an atherogenic dyslipidemia characterized by elevated 
triglycerides, a low HDL level, and glucose intolerance. Physicians should 
encourage their patients to take responsibility for behavior related to 
modifiable risk factors for development of premature atherosclerotic 
disease. Conscientious counseling and patient education may forestall 
the need for pharmacologic measures intended to reduce coronary 
risk.Adoption of hygienic life-style changes to ameliorate coronary risk 
entails little expense or possibility of adverse effects. In contrast, 
pharmacotherapy can prove costly. Although lipid-lowering drugs such 
as the HMG-CoA reductase inhibitors have proven exceedingly well 
tolerated in clinical trials, the use of these or other lipid-lowering agents 
could produce adverse reactions in some individuals. The decision to 
initiate drug treatment for reduction of risk of atherosclerotic events 
requires careful consideration, particularly in the setting of 
"primaryprevention" or in patients without known atherosclerotic 
disease. In this regard, it is prudent to consider not only the LDL 
cholesterol but also the individual patient's global cardiovascular risk.  
For example, an individual with an average LDL but a low HDL, 
hypertension, and a family history of premature coronary artery disease 
might warrant initiation of drug therapy more than an individual with 
the same LDL level in the absence of the other risk factors.  The 
calculation of coronary risk includes taking gender, smoking history, and 
systolic blood pressure into account, in addition to plasma cholesterol 
levels. This policy illustrates how estimations of global risk may be 
applied to optimize decisions regarding initiation  of drug therapy to 
prevent atherosclerotic events  
 CAROTID DOPPLER: 
Carotid  atherosclerotic  plaque  usually    involves the   internal 
carotid artery within 2 cm  of  the  carotid  bifurcation. This  location  is  
readily  amenable  to  exploration  by  ultrasound.Sonography can  
assess  plaque  morphology  such  as  hemorrhagic  plaque  which  is  a  
source  of  increased  thromboembolic  events.  The  diagnostic  work up 
of  carotid  disease  has  changed   dramatically  over  the  past  two  
decades.Carotid  sonography  has  largely  replaced   angoiography  as  
the  most  noninvasive  and  costeffective  screening  method  to  assess  
suspected  extracranial  carotid  atherosclerotic disease.Angiography is  
now  reserved  for  those  patients  in  whom  the  ultrasound  or  MRA  
is  inadequate.   Other  carotid  ultrasound  applications  are  evaluation  
of  carotid  bruitsmonitoring   progress  of known  atherosclerotic  
disease  assessment  during  or  after  endarterectomypreoperative  
screening prior to  major  vascular  surgeryNon  atherosclerotic  diseases  
can  be  evaluated  including  follow  up of  carotid  dissection evaluation  
of  Takayasu’s  arteritis  assessment   of    malignant  carotid   artery   
invasion. 
 PLAQUE  CHARECTERIZATION : 
      Atheromatous   carotid    plaques   should  be  carefully  evaluated  
to  determine  plaque  extent,  location,  surface contour  and  texture   
as  well  as  assessment  of luminal stenosis. 
              Plaque  texture  is  generally  classified  as  being  homogenous  
or  heterogenous. Homogenous  plaques  has  a  uniform  echo  pattern  
and  a  smooth  surface.The  uniform  echotexture   corresponds   
pathologically  to  dense  fibrous  connective  tissue.Calcified  plaque  
produces  posterior  acoustic  shadowing  and  is  common  in  
asymptomatic  individuals. Heterogenous  plaque  has  a more  complex  
echo  pattern  and  has  one  or  more  focal  sonolucent  areas.  
Hetrogenous  plaque  is  characterized  pathologically  by   intraplaque  
hemorrhage.Sonography  accurately  determines  the  prescence  of  
intraplaque  hemorrhage.  A  “Swiss  Cheese”  pattern with  multiple  
sonolucent  areas   is  charecterestic  of  intraplaque  hemorrhage. 
Sonographic  changes  that  suggest  plaque  ulceration  include  a  focal  
depression or  break  in  the  plaque  surface  or  an  anechoic  area  
within  the  plaque  which  extends  to  the  plaque  surface  without  an    
intervening  echo  between  the  vessel  lumen  and  the  anechoic  
plaque  region 
PLAQUE  MORPHOLOGY   ON CAROTID DOPPLER  .   
Type 1-  predominantly  echolucent   plaque,  with  a  thin  echogenic  
cap 
Type-2- substantially  echolucent  with  small   areas  of  echogenicity 
Type 3- predominantly  echogenic  with  small  areas  of  echolucency 
Type 4- uniformly  echogenic 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIALS AND METHODS 
 
This study was conducted in  forty dyslipidemic patients  who  attended 
the  Medicine OPD  at PSG Hospitals. 
 AIM OF THE STUDY       
The aim of the study is to determine wether CRP concentrations 
were correlating with  the prescence of atherosclerotic plaques in  a 
dyslipidemic population. 
INCLUSION CRITERIA 
The inclusion criteria were  as follows. 
Fasting  serum lipid values; 
       Total cholesterol   >  200mg/dl 
       Triglycerides >  150mg/dl 
 
 EXCLUSION CRITERIA 
Age   < 18  and  >70 years 
CRP >10mg/l[ represents clinically relevant inflammation] 
HDL > 70mg/dl 
 DETERMINATION OF C-REACTIVE PROTEIN 
• Specimen Collection 
     Only disposable glass tubes  were used for  sample  collection 
      Blood  samples were  collected with aseptic precautions into a plain 
glass tube 
• Method- Latex agglutination     
• Carotid Doppler 
              In the  supine  position, with the head turned away from  the  
sonographer  and the  neck extended  with  mild  rotation, each  patient 
systematically underwent ultrasonography of the extracranial carotid 
arteries by  use of a duplex system.The protocol consisted  of study of the 
right and left common and internal carotid arteries [ including 
bifurcations] with use of   8-11 mega hertz scanning frequency in B   -
mode  . Plaque was defined as an echogenic structure encroaching the 
vessel lumen with a distinct  area  50% greater than the intimal plus 
medial thickness of neighbouring sites.  
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RESULTS AND ANALYSIS 
TABLE SHOWING CRP LEVELS AND CAROTID DOPPLER FINDINGS 
SERIAL 
NO 
AGE 
[YEARS] 
SEX CRP 
LEVELS(mg/dl) 
CAROTID DOPPLER 
1 45 F 0.6 NO PLAQUE 
2 55 M 0.6 NO PLAQUE 
3 48 F 0.6 NO PLAQUE 
4 50 F 0.7 NO PLAQUE 
5 55 F 0.6 NO PLAQUE 
6 60 M 0.8 NO PLAQUE 
7 58 M 0.7 NO PLAQUE 
8 51 M 0.6 NO PLAQUE 
9 60 F 0.7 NO PLAQUE 
10 62 M 0.8 NO PLAQUE 
11 41 F 0.6 NO PLAQUE 
12 54 M 0.6 NO PLAQUE 
13 49 F 0.7 NO PLAQUE 
14 43 F 0.6 NO PLAQUE 
15 54 F 0.6 NO PLAQUE 
16 43 M 0.7 NO PLAQUE 
17 45 M 0.6 NO PLAQUE 
18 55 M 0.6 NO PLAQUE 
19 65 F 0.7 NO PLAQUE 
20 56 F 0.6 NO PLAQUE 
21 54 M 0.6 NO PLAQUE 
22 55 M 0.7 NO PLAQUE 
23 56 F 0.6 NO PLAQUE 
24 65 F 0.6 NO PLAQUE 
25 58 M 0.7 1CM x 2.1MM-POSTERIOR 
WALL 0F LEFT ICA 
26 65 M 0.6 3CM x 2 MM-POSTERIOR 
WALL OF LEFT ICA 
27 68 M 1.2 2.5MM x  1.3CM-
POSTERIOR WALL OF 
RIGHT CCA 
28 54 F 0.6 2MM x 3MM  -POSTERIOR 
WALL OF LEFT CCA  
29 67 M 1.1 1MM  x 2MM-POSTERIOR 
WALL LEFT  ICA-ORIGIN 
30 58 M 1.2 1.6CM x 3 CM-POSTERIOR 
WALL-LEFT ICA ORIGIN 
31 60 M 0.6 1.5CM  x 3MM-ORIGIN OF 
LEFT ICA 
 
32 62   M 0.8 1CM x 3CM-POSTERIOR 
WALLOF RIGHT ICA 
33 67 F 1.2 1CM x 4CM-ANTERIOR 
WALL OF RIGHT CCA 
34 69 M 1.2 2CM x 3CM-POSTERIOR 
WALL OF LEFT ICA ORIGIN 
AND 1CM x 3CMM 
POSTERIOR WALL OF 
RIGHT ICA  
35 65 F 0.6. 2MM x 3CM ORIGIN OF 
CCA RIGHT SIDE 
36 66 M 0.5 1CM x  1CM  POSTERIOR 
WALL OF RIGHT CCA 
ORIGIN 
37 58 F 1.2 3CM x 1CMORIGIN OF 
RIGHT 
 ICA 
38 65 M 0.6 3MM x 2MM-ANTERIOR 
WALL OF RIGHT CCA 
39 65 M 0.6 1CM x 1CM DISTAL RIGHT 
CCA 
40 63 F 0.8 2CM X 1CM DISTAL LEFT 
CCA 
 
 
 MEAN  CRP LEVELS IN  DYSLIPIDEMIC PATIENTS WITHOUT  PLAQUE 
AND WITH PLAQUE 
CASE[DYSLIPIDEMIC 
PATIENTS] 
NO OF 
CASES 
MEAN CRP 
LEVELS(MG/DL) 
WITHOUT PLAQUE 24 0.617 
WITH PLAQUE 16 0.869 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 STATISTICS 
          
                  The results of forty patients were analysed.Twenty four of the 
patients did not have plaques .Sixteen of them had plaques.The mean 
CRP of both the set of patients were calculated.The standard  deviation w 
as calculated. The results were analysed  by subjecting it to the null 
hypothesis. The null hypothesis was rejected and the p value was found 
to be significant.[p value - <0.001 / t value-3.9].So CRP was found to 
correlate with prescence of atherosclerosis in dyslipedemic patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                              DISCUSSION 
    
CORRELATION OF CRP WITH ATHEROSCLEROSIS IN 
DYSLIPEDEMIC PATIENTS 
 
In this study the relationship between CRP and carotid atherosclerosis 
was evaluated       and was found to correlate. 
                       
   The Bruneck study(4) was a study done to study the etiology and 
epidemiology of carotid atherosclerosis. In this study 125 men and 125 
women  were selected who were between the ages 40-79 years.Their risk 
factor profile were evaluated. The risk factors which were evaluated 
included diabetes,hypertension and smoking.A biochemical evaluation of 
other risk factors was also performed.It included lipid levels,acute phase 
reactants such as CRP, D-Dimer.lipoprotein-a.Every patient underwent a 
carotid doppler study of the common carotid arteries, origins of the 
internal and external carotid arteries. 
The conclusion drawn from the study was that atherosclerosis was of two 
types.One type was a chronic progressive lesion .This was a marker for 
early atherosclerosis.The  risk  factors which correlated positively for 
these type of lesions included diabetes,hypertension,dyslipidemia .The 
levels of CRP was also found to correlate with  carotid atherosclerosis in 
this study. 
           Otherwise there are very few studies comparing CRP with carotid 
atherosclerosis. There have been other studies comparing CRP with 
atherosclerosis in other vascular territories such as the coronaries and 
peripheral limb vessels.A few of these studies are being quoted here. 
            Studies have revealed that CRP has been associated with cardiac 
conditions such as chronic stable angina as well as acute events 
associated with atherosclerosis such as the spectrum of acute  coronary 
syndromes  compromising of conditions such as unstable angina,acute 
myocardial infarction and non  ST elevation myocardial infarction. 
                       In one study by Nader Rifas,(45) Rana Joubran 100 
patients were selected who had angiographically proven coronary artery 
disease.Each patient had a minimum of one vessel involvement with at 
least a 50% block.These patients were evaluated for risk factors for 
coronary atherosclerosis and were subjected to other  biochemical 
investigations which included C-Reactive Protein.The results of the study 
showed that C-Reactive proteins  levels  were increased in the patients 
who had angiographically proven coronary artery disease compared to 
the controls.But in this study C –Reactive protein levels  did not correlate 
with the severity of the atherosclerosis that is C-Reactive protein levels 
were not any higher in patients with a more severe block compared with 
patients with a lesser degree of block.This study supports the fact that C-
Reactive protein is a marker of diffuse atherosclerosis. 
                In a study by Heinrich T,Schulte H,(5) 929 patients were 
selected from patients who were admitted into a coronary rehabilitation 
unit.The extent of their coronary atherosclerosis was evaluated by means 
of a coronary angiogram, the extent of extracranial cerebrovascular 
disease by means of B-mode ultrasound and the extent of peripheral 
vascular disease by means of  baseline and stress oscillography.The 
results of this study showed that C-Reactive Protein levels correlated 
with the prescence of cerebrovascular and peripheral vascular disease. 
 
                   In another study by Thompson SG,Kienast SG(1) about 3500 
patients who had chronic stable angina were selected.All these patients 
underwent a angiographic procedure. They were also subjected a series 
of biochemical analysis which included CRP and other tests such as 
fibrinogen , tissue plasminogen activator inhibitor, protein c and protein 
s  .The patients were then prospectively followed up for a period of time 
and the end point was the occurrence of acute events such as myocardial 
infarction and sudden cardiac deaths.  The results of the studies showed 
that  CRP correlated with the occurrence of acute coronary events in 
patients with chronic stable angina . 
 
       In a study by Paul.M.Ridker (2) the association between C-Reactive 
Protein and Peripheral Vascular Disease was studied in which 144 
apparently healthy men who underwent baseline CRP measurements and 
were subsequently followed .up.The results of the studies showed that 
CRP levels were higher at baseline in those patients who went on to 
develop peripheral vascular disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                           CONCLUSION 
 
 This study was conducted on fourty dyslipidemic patients at  PSG 
Hospitals, Coimbatore. 
                 All patients were subjected to a biochemical test in the form of 
C-Reactive Protein and simultaneously subjected to a carotid Doppler 
study by means of ultrasound. 
                 The C-Reactive Protein levels  among  patients with 
atherosclerotic plaques was found to be higher than in patients without 
plaques.[p value< 0.001].The mean value of the CRP in patients without 
carotid plaques was found to be 0.61 and the mean values in the 
patients with carotid plaques was found to be0.86. 
                       Literature review  showed  few studies which showed an 
association between CRP levels and carotid atherosclerosis . There were 
other studies which showed association between CRP levels  and 
atherosclerosis in other vascular beds  such as the coronary circulation 
and the peripheral circulation. 
                         The present study  showed the correlation of C-Reactive 
Protein levels with the prescence of carotid atherosclerosis. 
                         Whether C-Reactive Protein can be used routinely in 
patients as a risk factor for., atherosclerosis  is still a matter of debate 
although many trials have proved the association  of C-Reactive Protein 
with atherosclerosis in various vascular beds such as coronary,cerebral 
and peripheral vascular beds.Most of the studies in relation to C-Reactive 
Protein has been done in patients with coronary atherosclerosis  , more 
studies are required to prove it’s association in other vascular beds. 
                               It can thus be concluded that C-Reactive  Protein is 
a marker of  carotid  atherosclerosis in patients with dyslipidemia which 
is an important risk factor for atherosclerosis.  
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